Form 8-K - Current report:
SEC Accession No. 0000950170-24-126288
Filing Date
2024-11-13
Accepted
2024-11-13 16:05:08
Documents
14
Period of Report
2024-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eq-20241113.htm   iXBRL 8-K 47177
2 EX-99.1 eq-ex99_1.htm EX-99.1 151125
3 GRAPHIC img162018617_0.jpg GRAPHIC 152496
4 GRAPHIC img162018617_1.jpg GRAPHIC 152496
  Complete submission text file 0000950170-24-126288.txt   746753

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eq-20241113.xsd EX-101.SCH 27812
16 EXTRACTED XBRL INSTANCE DOCUMENT eq-20241113_htm.xml XML 4704
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 105 LA JOLLA CA 92037 (858) 412-5302
Equillium, Inc. (Filer) CIK: 0001746466 (see all company filings)

EIN.: 821554746 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38692 | Film No.: 241453973
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)